Summary. In studies which have involved determination of fractional inhibitory concentrations, synergy has been described between the 4-quinolones, which inhibit the A subunit of DNA gyrase, and either coumermycin or novobiocin, which inhibit the B subunit of the same enzyme. In this study, fixed concentrations of ciprofloxacin or ofloxacin were combined with varying concentrations of coumermycin or novobiocin and vice versa in nutrient broth. The bactericidal activities of the different mixtures against either Staphylococcus aureus E3T or S. warneri were determined and found to be less than those of equivalent concentrations of either 4-quinolone alone. The observation that gyrase B subunit inhibitors antagonised the bactericidal activity of 4-quinolones is in accordance with the report previously made by others that ciprofloxacin combined with coumermycin was less effective than ciprofloxacin alone in treating staphylococcal endocarditis in rats. Our results indicate that both inhibitory and bactericidal activity should be taken into account when assessing possible interactions in vivo between 4-quinolones and other antimicrobial agents.
Introduction
DNA gyrase is the only bacterial enzyme that is known to be capable of introducing negative supercoils into DNA. ' The enzyme is a tetramer consisting of two A and two B subunits coded for by the gyrA and gyrB genes respectively.' The enzyme appears to be highly conserved because a high degree of sequence homology has been found in the gyrase genes of different species including Staphylococcus aureus and Escherichia coli.192 However, there appear to be some differences in genetic organisation because the gyrA and gyrB genes are contiguous in S. aureus but map separately in E. coli. 2 Coumermycin and novobiocin are inhibitors of the B subunits of DNA gyrase. In contrast, the 4-quinolones act primarily on the A subunit, '93 although they may bind to DNA rather than to the enzyme i t~e l f .~ Fractional minimum inhibitory concentration (FIC) studies have shown that these two classes of drugs can act synergically against both gram-negative and gram-positive bacteria, including S . aureus, i.e., the activity of both drugs together is significantly greater than that of either drug acting alone in the same concentration. 596 However, in-vivo experiments have shown that ciprofloxacin alone is more effective than ciprofloxacin plus coumermycin in treating S . aureus endocarditis in ratsq7
Studies of minimum inhibitory concentrations (MICs) and FICs of drugs assess their effects on the inhibition of bacterial multiplication. The 4-quinolones not only inhibit bacterial multiplication but are rapidly bactericidal at concentrations above the MIC.' The bactericidal and bacteriostatic activities of the 4-quinolones are distinct in that some drugs do not affect the inhibition of bacterial multiplication by these compounds but do reduce their bactericidal activity.8y9 In addition, magnesium severely antagonises the bactericidal activity of 4-quinolones but has little effect on their bacteriostatic potencies. l o This is in contrast with low pH which antagonises the static much more than the bactericidal activity of ciprofloxacin. ' ' Therefore, the effects of two gyrase B subunit inhibitors, novobiocin and coumermycin, on the bactericidal activities of ciprofloxacin and ofloxacin against S. aureus and S . warneri were investigated in vitro and results were compared with the in-vivo findings of Perronne et al.7
Materials and methods

Bacterial strains
S. aureus E3T and S . warneri, which have been used to investigate the bactericidal activities of ciprofloxacin and ofloxacin in previous studies,' were chosen as the test organisms. The strains were kept on drugfree nutrient agar and subcultured every 10 days. Colonies taken directly from drug-free nutrient agar 
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were used to prepare the overnight cultures used in these experiments.
Determination of antibacterial activity
Ciprofloxacin (Bayer) and novobiocin (Upjohn) were dissolved in sterile distilled water. Ofloxacin (Hoechst) was dissolved in 0-5 M NaOH 0.02 ml/mg and coumermycin (Roche) in dimethylsulphoxide before being made up to the appropriate concentration in sterile distilled water.
The bactericidal activities of these four agents were examined in Nutrient Broth (Oxoid) with incubation at 37°C over a 3 h period. The results of mixing the two classes of drugs were determined by combining a gyrase B subunit inhibitor at a range of concentrations with a fixed concentration of a 4-quinolone and vice versa. The fixed concentrations of 4-quinolones used were the optimum bactericidal concentrations (OBCs), defined as the drug concentrations that produced the most rapid killing of bacteria under these test conditions. The fixed concentration of coumermycin investigated was 0.9 mg/L which was found in rat serum 24h after the administration of a 4 mg/Kg by Peronne et ~1 .~
The fixed concentration of novobiocin used, 15 mg/L, is achieved in human serum after oral administration of a single 500-mg dose. Survival of bacteria was estimated by performing viable counts on nutrient agar as previously described. l4 All experiments were performed in duplicate but only the first set of results for each experiment are presented here as there was minimal variation between the two sets of data.
Results
The bactericidal activities of ciprofloxacin or ofloxacin alone against either S . aureus or S . warneri measured after 3 h were considerably greater than those of either coumermycin or novobiocin at the concentrations which were fixed in later combination studies (figs. 1, 2). There was little difference between bactericidal activities of the two 4-quinolones (at their OBC) against the staphylococci. Coumermycin 0.9 mg/L displayed greater bactericidal activity than novobiocin 15 mg/L against both species. With S . aureus, when these concentrations of coumermycin or novobiocin were combined with the OBCs of ciprofloxacin or ofloxacin, the bactericidal activity of each mixture, while slightly greater than that of either gyrase B subunit inhibitor alone, was much less than that of either 4-quinolone alone ( fig. 1) . With S . warneri, when novobiocin was combined with ciprofloxacin or ofloxacin, the bactericidal activity of each mixture was also much less than that of either 4-quinolone alone and slightly greater than that of novobiocin alone ( fig. 2 ). However, with S . warneri, even greater antagonism occurred when coumermycin was combined with ciprofloxacin or ofloxacin; the bactericidal activity of each mixture was not only less than that of either 4-quinolone alone but was also less than that of coumermycin alone ( fig. 2 ). The addition of coumermycin at a range of concentrations 0.05-9 mg/L to either ciprofloxacin or ofloxacin in nutrient broth at their OBCs against S . aureus or S . warneri reduced the bactericidal activities of the 4-quinolones by 10-fold or more after exposure for 3 h ( figs. 3 and 4) . The bactericidal activities of mixtures containing coumermycin 0.9 mg/L or novobiocin plus ciprofloxacin at a range of concentrations against S . aureus were less than those of the 4-quinolone alone at all concentrations above 0.15 mg/ Similarly, with S . warneri, coumermycin 0.9 mg/L or novobiocin 15 mg/L antagonised the bactericidal activities of the 4-quinolone when combined with concentrations exceeding 0.3 mg/L ( fig. 6) .
L (fig. 5).
Discussion
In the experiments described, ciprofloxacin and ofloxacin were found to reduce the percentage of both S . aureus E3T and S . warneri that survived after 3 h far more efficiently than coumermycin or novobiocin at the concentrations tested. Bactericidal activities of mixtures of fixed concentrations the two classes of drugs were less than those of ciprofloxacin or ofloxacin alone. The bactericidal activity of either 4-quinolone at its OBC was reduced by 10-fold or more in the presence of increasing concentrations of coumermycin. When a single concentration of coumermycin or novobiocin was combined with increasing amounts of ciprofloxacin, the bactericidal activity of the mixture was always less than that of the 4-quinolone alone at any concentration above 0.3 mg/L. A possible explanation for this observation of antagonism of the bactericidal activity of the 4-quinolones by the gyrase B subunit inhibitors may be the effect of the drugs on DNA supercoiling. Negatively supercoiled DNA, which provides a better template for DNA-dependent RNA polymerase than relaxed DNA,' is thought to be required for the full bactericidal activity of the 4-quinolones because this has been shown to be reduced when RNA synthesis is inhibited in in-vitro studies.* Mixtures of the two classes of drug might markedly reduce RNA synthesis by causing a greater reduction in chromosomal supercoiling than the 4-quinolones alone. This pro- posal is consistent with FIC measurements that indicate that synergy occurs between the B subunit antagonists and the 4 -q u i n o l o n e~,~~~ as inhibition of RNA synthesis has no effect on the bacteriostatic activity of the 4-quinolones.* The antagonism of the killing activity of ciproflbxacin by coumermycin may explain the observation of Perrone et al.7 that ciprofloxacin alone was better than the combination of ciprofloxacin with coumermycin for treating S . aureus endocarditis in rats.7 Coumermycin at a concentration that would have been present in rats 24 h after administration7 was sufficient to reduce the bactericidal activity of ciprofloxacin at its OBC by around 10-fold in the experiments described above. The bactericidal activity of coumermycin alone was less than that of coumermycin plus a 4-quinolone presumably because R N A synthesis is only moderately reduced in the mixture so that the superior bactericidal activity of the 4-quinolone could still contribute to the results. This in-vitro observation is in agreement with the finding of Perrone et al.7 that the combination of ciprofloxacin and coumermycin was better than coumermycin alone in treating endocarditis in rats. Although coumermycin itself is no longer being developed for clinical use,7 the results of this investigation may have clinical implications. Several studies have shown little interaction between the 4-quinolones and many other antibacterial agents, as judged by measurements of FICs. However, the bactericidal activity of the 4-quinolones can be significantly affected by certain other antimicrobial agents.899916y17 Any interaction that brings about a decrease in the bactericidal activity of the 4-quinolones may have an important detrimental effect on clinical outcome of combination therapy. Indeed, the results obtained in this study correlate well with the clinical outcome as measured in an experimental animal model. Therefore, it would seem prudent to investigate both the inhibitory and bactericidal activities of combinations of the 4-quinolones with other antimicrobial agents in order to assess fully the possibility of a significant invivo interaction.
